New research supports the therapeutic potential of repetitive transcranial magnetic stimulation (rTMS) for Alzheimer’s disease (AD).
In a 52-week phase 2 trial, personalized rTMS applied over the precuneus, a core component of the default mode network (DMN), slowed the progression of cognitive and functional decline in patients with mild to moderate AD.
“These latest results provide new additional evidence...supporting the potential for neuromodulation of the DMN to slow the impairment of cognitive functions, preserve activities of daily living, and reduce behavioral disturbances in Alzheimer’s patients, with no significant side effects,” Giacomo Koch, MD, PhD, professor of physiology, University of Ferrara, Ferrara, Italy, and director of the Brain Stimulation Laboratory, Santa Lucia Foundation, said in a statement.
The results were presented at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference.
Comments